{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:19:50Z","timestamp":1762867190993},"reference-count":28,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glecaprevir and pibrentasvir are direct\u2010acting antiviral agents being developed as combination therapy for the treatment of chronic hepatitis C virus infection. The aim of the present studies was to assess the effect of race and ethnicity (white, Han Chinese, Japanese) on the pharmacokinetics and safety of multiple oral doses of glecaprevir and pibrentasvir given alone and in combination. Two multiple\u2010dose, single\u2010center, phase 1 studies were conducted in healthy adult male and female subjects (n = 170) of respective Asian and white race\/ethnicity. Glecaprevir (100, 200, 300, or 700\u00a0mg once daily) and pibrentasvir (80, 120, or 160\u00a0mg once daily) were administered alone for 7 days followed by the combination of both direct\u2010acting antiviral agents for another 7 days. Intensive blood sampling was performed, and pharmacokinetic parameters were estimated by noncompartmental analyses. ANOVA was employed to evaluate for differences of steady\u2010state glecaprevir and pibrentasvir exposures between Asian (Japanese or Han Chinese) and white subjects. Glecaprevir and pibrentasvir exposures in Han Chinese and Japanese were similar to those in whites across dose levels. The nonlinear dose\u2010exposure relationships for glecaprevir and pibrentasvir were similar across Japanese, Han Chinese, and white subjects, and the safety profiles of the agents were comparable across these groups. The results of these studies demonstrate that race\/ethnicity has no clinically meaningful impact on direct\u2010acting antiviral agent exposures, safety, or tolerability of the glecaprevir and pibrentasvir combination. This is supported in part by the large global registration program of the pangenotypic, coformulated fixed\u2010dose glecaprevir\/pibrentasvir regimen and allows for inclusion of diverse ethnic populations.<\/jats:p>","DOI":"10.1002\/jcph.959","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T12:52:40Z","timestamp":1502455960000},"page":"1616-1624","source":"Crossref","is-referenced-by-count":14,"title":["Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects"],"prefix":"10.1002","volume":"57","author":[{"given":"Chih\u2010Wei","family":"Lin","sequence":"first","affiliation":[{"name":"Clinical Pharmacology and Pharmacometrics AbbVie  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Dutta","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacometrics AbbVie  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bifeng","family":"Ding","sequence":"additional","affiliation":[{"name":"Data and Statistical Science AbbVie  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianli","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacometrics AbbVie  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neddie","family":"Zadeikis","sequence":"additional","affiliation":[{"name":"Infectious Diseases AbbVie  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armen","family":"Asatryan","sequence":"additional","affiliation":[{"name":"Infectious Diseases AbbVie  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Kort","sequence":"additional","affiliation":[{"name":"Medical Affairs AbbVie  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Campbell","sequence":"additional","affiliation":[{"name":"Infectious Diseases AbbVie  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Podsadecki","sequence":"additional","affiliation":[{"name":"Infectious Diseases AbbVie  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacometrics AbbVie  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,8,11]]},"reference":[{"issue":"1","key":"e_1_2_8_2_1","first-page":"372A","article-title":"Polaris Observatory\u2010global prevalence of hepatitis C","volume":"64","author":"Blach S EC","year":"2016","journal-title":"Hepatology"},{"key":"e_1_2_8_3_1","volume-title":"Hepatitis C Fact Sheet","author":"World Health Organization","year":"2016"},{"key":"e_1_2_8_4_1","unstructured":"NgT ReischT MiddletonT McDanielK et\u00a0al.ABT\u2010493 a potent HCV NS3\/4A Ppotease inhibitor with broad genotype coverage. Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 3\u20106 2014; Boston MA."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2016.10.007"},{"key":"e_1_2_8_6_1","unstructured":"Ng TKP KatiW ReischT et\u00a0al.ABT\u2010530 an HCV NS5A inhibitor with potent pangenotypic activity and high geneti c barrier to resistance. Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 3\u20136 2014; Boston MA."},{"key":"e_1_2_8_7_1","article-title":"Pharmacokinetics and tolerability following single and multiple doses of ABT\u2010530 in a first\u2010in\u2010human study [published online ahead of print 2017]","author":"Lin C\u2010W","journal-title":"Clin Pharmacol Drug Dev"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30918-1"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.07.020"},{"key":"e_1_2_8_10_1","article-title":"Asatryan. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis [published online ahead of print 2017]","author":"Kwo PY","journal-title":"J Hepatol"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","unstructured":"Kosloski MPDS ZhaoW PgatchD MensaF KortJ LiuW.Pharmacokinetics safety and tolerability of next generation direct acting antivirals ABT\u2010493 and ABT\u2010530 in subjects with renal impairment. Paper presented at: The International Liver Congress; European Association for the Study of the Liver (EASL); April 13\u201317 2016; Barcelona Spain.","DOI":"10.1016\/S0168-8278(16)00643-7"},{"key":"e_1_2_8_13_1","unstructured":"Gane ELE PugatchD Papatheodoridis G et\u00a0al.EXPEDITION\u20104: efficacy and safety of glecaprevir\/pibrentasvir (ABT\u2010493\/ABT\u2010530) in patients with renal impairment and chronic hepatitis C virus genotype 1\u20106 infection. Paper presented at: The Liver Meeting: American Association for the Study of Liver Diseases (AASLD); November 11\u201315 2016; Boston Massachusetts."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29081"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1800-0"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.06.013"},{"key":"e_1_2_8_17_1","unstructured":"2016 Janssen Therapeutics Titusville NJ Olysio\u2122 (simeprevir) [US package insert]"},{"key":"e_1_2_8_18_1","unstructured":"Viekira Pak (ombitasvir paritaprevir and ritonavir tablets; dasabuvir tablets) [US package insert]. North Chicago IL: AbbVie Inc; 2016.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206619lbl.pdf. Accessed November 10 2016."},{"key":"e_1_2_8_19_1","unstructured":"Zepatier\u2122 (elbasvir and grazoprevir) [US package insert]. Whitehouse Station NJ: Merck & Co Inc.; 2016.https:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_pi.pdf."},{"key":"e_1_2_8_20_1","unstructured":"GarimellaTGY HeB MoL IshikawaH.Evaluation of daclatasvir and asunaprevir exposures in Japanese non\u2010Japanese Asians and non\u2010Asians. Paper presented at: Conference of the Asian Pacific Association for the Study of the Liver (APASL); February 20\u201324 2016; Tokyo Japan."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0299-6"},{"key":"e_1_2_8_22_1","first-page":"241","article-title":"Simeprevir for the treatment of hepatitis C virus infection","volume":"7","author":"Izquierdo L","year":"2014","journal-title":"Pharmacogenom Pers Med"},{"key":"e_1_2_8_23_1","unstructured":"Kawada NSF KarinoY ChayamaK et al.Efficacy safety and pharmacokinetics of grazoprevir (MK\u20105172) and elbasvir (MK\u20108742) in hepatitis C genotype 1 infected non\u2010cirrhotic Japanese patients (phase 2 portion in phase 2\/3 combined study). Paper presented at: American Association for the Study of Liver Diseases (AASLD); November 13\u201017 2015; San Francisco California."},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-015-9846-1"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0423-2"},{"key":"e_1_2_8_26_1","volume-title":"Viekirax. Summary of product characteristics","year":"2015"},{"key":"e_1_2_8_27_1","unstructured":"Sunvepra (asunaprevir) [Japan prescribing information]. Bristol\u2010Myers KK; 2014."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02264-15"},{"key":"e_1_2_8_29_1","doi-asserted-by":"crossref","unstructured":"Puoti MFG WangS MutimerD et al.High SVR rates with eight and twelve weeks of pangenotypic glecaprevir\/pibrentasvir: integrated efficacy analysis of genotype 1\u20136 patients without cirrhosis. Paper presented at: The International Liver Conference: European Association for the Study of Liver (EASL); April 19\u201323 2017; Amsterdam The Netherlands.","DOI":"10.1016\/S0168-8278(17)31927-X"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.959","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T16:46:27Z","timestamp":1695746787000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1002\/jcph.959"],"URL":"https:\/\/doi.org\/10.1002\/jcph.959","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}